Abstract 126: Effect of active cytomegalovirus infection on symptoms of fatigue, cancer-related cognitive impairment, and peripheral neuropathy in ovarian cancer survivors
Authors: Li Xuan , Brown Katherine , Honeyfield Kate , Hunter-Schlichting Devon , Gruner Morgan , Teoh Deanna , Geller Melissa , Nelson Heather , Vogel Rachel I. 
Published: March 2024

Abstract
Background: Fatigue, cancer-related cognitive impairment (CRCI) and neuropathy are among the most common and distressing side effects reported by individuals treated with chemotherapy for ovarian cancer. Cytomegalovirus (CMV) is a highly prevalent herpes virus infection worldwide, affects inflammation and immune function, and can reactivate with treatment for cancer. This study aimed to explore the associations between active CMV infection and patient-reported symptoms among ovarian cancer survivors who have completed front-line chemotherapy.
Methods: We conducted a cross-sectional study among individuals with a history of a diagnosis of ovarian cancer, primary peritoneal cancer, or fallopian tube cancer from academic and community cancer clinics in Minnesota at any time point after completion of front-line chemotherapy. Participants completed a one-time survey and provided a blood sample. The exposure of interest was plasma CMV DNA level measured using digital PCR, with ≥100 copies/mL of plasma considered active infection (CMV+). We measured symptoms of fatigue (Fatigue Symptom Inventory), CRCI (PROMIS Cognitive Function 8a) and peripheral neuropathy (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity) using validated self-reported measures. Data were analyzed using descriptive statistics and compared by active CMV infection status (CMV+ vs. CMV-) in the full group and by treatment status (receipt of chemotherapy within 30 days prior to data collection) using t-tests.
Results: A total of 160 participants were analyzed. Participants were median of 64.0 years old and 2.3 years from initial diagnosis. Most (75.2%) had advanced stage disease, 43.8% had experienced at least one recurrence, and 40.0% received chemotherapy within 30 days prior to participation. Overall, 40.0% were CMV+, with 40.6% CMV+ among those who received chemotherapy within 30 days and 39.6% CMV+ among those who had not. Participants who were CMV+, compared to those who were CMV-, had overall worse symptoms, with greater symptoms of neuropathy in the full group (11.9±9.2 vs. 9.1±7.8, p=0.04) and particularly greater symptoms of CRCI among those who had recently received chemotherapy (29.2±7.4 vs. 33.2±6.7, p=0.03).
Conclusion: We identified that active CMV infection is common in this survivor population and found that worse symptoms of neuropathy and CRCI are associated with CMV+ status. These results are consistent with studies among other immune-compromised populations, and with further validation, provide a potential therapeutic path for reducing these symptoms.
Citation Format: Xuan Li, Katherine Brown, Kate Honeyfield, Devon Hunter-Schlichting, Morgan Gruner, Deanna Teoh, Melissa Geller, Heather Nelson, Rachel I. Vogel. Effect of active cytomegalovirus infection on symptoms of fatigue, cancer-related cognitive impairment, and peripheral neuropathy in ovarian cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 126.